SCHOTT Pharma AG & Co. KGaA : Strong performance at Delivery Systems leads to an increase in guidance
>Especially DDS topped estimates - At the group level Q3 2024 reported sales of € 254m (+15%; +21% at cc) came in 3% above our and 4% above the consensus. Reported adj. EBITDA of € 74m (+35%) was 7% above our estimates and 12% above the consensus. The share of profitable High Value Solutions (HVS) 2024 increased to 53% (vs 51% in Q3 2023), in line with our estimates. Looking at the single divisions, especially Drug Delivery Systems (DDS) came in stronger than expected...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.